SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genzyme Tissue Repair (GZTR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: wiz who wrote (2470)1/16/1999 9:39:00 PM
From: Bobb  Read Replies (1) of 2553
 
Mark:

I defer to your explanation. My sister had a replacement ligament from a cadaver and it was several months of grueling therapy before she regained her full range of motion. That was about 3 years ago. Although she walks without difficulty, I wonder if she uses her injury as an excuse to avoid aerobic exercise. She's gained a lot of weight.

Cartilage is the stuff Carticel repairs, but there is some question whether the material grown outside the body will adhere to damaged, i.e., arthritic bone. That is why at present Carticel is not indicated to repair arthritic knees. Still there is a big group of generally younger adults with cartilage damage that would benefit from Carticel. At least that's what management keeps telling us.

But if they develop a arthroscopic procedure and one that would help arthritis sufferers, this stock will skyrocket. It might even make it all the way up to 4! Heck, maybe 4.5!

Go GENZL GO

Bobb
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News